Phase 3 Open-Label Stdy to Eval Switch Opt Stable Antiretro Reg Cont Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
Clinical Trial Grant
Administered By
Medicine, Infectious Diseases
Awarded By
Gilead Sciences, Inc.
Start Date
December 1, 2013
End Date
September 18, 2017
Administered By
Medicine, Infectious Diseases
Awarded By
Gilead Sciences, Inc.
Start Date
December 1, 2013
End Date
September 18, 2017